Hemab Therapeutics Holdings, Inc.
COAG Nasdaq
SEC CIK 2114044
Follow Hemab Therapeutics
Weekly email: filings, results
Net income
−$27.3M
−60% vs same quarter last year
EPS, diluted
−$0.58
+96.8% vs same quarter last year
Operating cash flow
−$28.3M
−72.6% vs same quarter last year
Operating income
−$29.8M
−74.5% vs same quarter last year
Source: SEC XBRL filings · latest filing